Roche snags CE mark for EGFR mutation test; Veritas Genetics launches $999 whole genome sequencing;

> Roche ($RHHBY) nabbed a CE mark for its cobas EGFR mutation test for plasma or tissue samples. Statement

> Veritas Genetics is allowing individuals in the Personal Genome Project to get their whole genome sequenced for less than $1,000. More

> Long-beleaguered Health Diagnostic Laboratory (HDL) sold its commercial testing facility to Oncimmune, allowing the latter to get its hands on HDL's EarlyCDT-Lung test for cancer. More

> Myriad Genetics ($MYGN) touted promising data for its companion diagnostic and prostate cancer tests at the recent European Society for Medical Oncology (ESMO) meeting. Statement

> The in vitro diagnostic (IVD) market for cancer is expected to grow to $8.3 billion by 2019, according to a new report. More

And Finally… Some cancer experts are questioning the validity of liquid biopsy tests, especially in light of the FDA's letter to Pathway Genomics over its related product. Story (sub. req.)